← Compound index
COMPOUND RECORD / VILOSEN

VilosenВилозен

A nonprotein extract from animal thymus, also spelled Vilozen, studied in historical human immune research.

Source linked

What the studies found

Observational study · 1990

The effect of vilozen on the immune status of bronchial asthma patients

Reported response
Immune correction and clinical improvement described in atopic-associated asthma; no response rate supplied

The report describes immune abnormalities in 163 asthma patients and improvement with adjunctive Vilosen in atopic-associated asthma. It supplies no treated-arm denominator or numerical symptom response.

Study notes · methods, sources and limitations

Participants or model 163 bronchial-asthma patients underwent immune assessment; the abstract does not specify how many received Vilosen.

Design 163 bronchial-asthma patients underwent immune assessment; the abstract does not specify how many received Vilosen.

Assessed population
163 patients; treated subset not stated

Important limitations

  • The 163 assessed patients are not a verified treatment-arm count. Background treatment and uncontrolled selection prevent attributing clinical benefit to the extract alone.

Vrachebnoe delo 1990 · Journal publication

Original source or citation ↗

Study results and tables ↗

Comparison in people · 1993

The immunomodulating effect of vilozen and splenin in the treatment of patients with acute and chronic toxic-allergic hepatitis

Combination result
Faster clinical-index and immune-homeostasis normalization reported; no numerical effect supplied

Vilosen plus Splenin was reported to speed clinical and immune normalization when added to usual hepatitis treatment. Of 181 patients assessed, 60 are explicitly described as receiving the combination.

Study notes · methods, sources and limitations

Participants or model 65 acute and 116 chronic toxic-allergic hepatitis patients examined; 20 acute and 40 chronic patients received add-on Vilosen plus Splenin.

Design 65 acute and 116 chronic toxic-allergic hepatitis patients examined; 20 acute and 40 chronic patients received add-on Vilosen plus Splenin.

Explicitly treated subset
20 acute + 40 chronic patients
Treatment course
10–15 days; Vilosen plus intramuscular Splenin and usual care

Important limitations

  • No numerical between-group outcome or allocation method is supplied. Splenin and background therapy prevent isolating Vilosen. The abstract’s intranasal/sublingual dose wording is ambiguous.

Likars'ka sprava 1993 · Journal publication

Original source or citation ↗

Study results and tables ↗

Observational study · 1996

The efficacy of immunomodulating therapy in patients with chronic cholestatic liver diseases

Clinical findings
Improved clinical measures and longer remission reported; no duration supplied

The combined extract regimen was associated with improved immune and microcirculatory measures and longer remission in chronic cholestatic liver disease. The abstract gives no remission duration or response percentage.

Study notes · methods, sources and limitations

Participants or model 93 patients with chronic cholestatic liver disorders; combined Splenin/Vilosen treatment.

Design 93 patients with chronic cholestatic liver disorders; combined Splenin/Vilosen treatment.

Study population
93 patients

Important limitations

  • No isolated Vilosen arm or numerical clinical comparison is described.

Likars'ka sprava 1996 · Journal publication

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Vilosen

Identity / background source ↗

Research background

Animal-thymus nonprotein extract reported in asthma, hepatitis and immune research. Historical clinical reports include combinations with Splenin; it is distinct from synthetic Vilon.

Compound class
Peptide / preparation research
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
See individual study records
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

Historical adjunctive reports; treated subsets and comparator details vary

Study methods

Three original clinical abstracts; no isolated effect established for combination regimens

Independent replication

Related reports are not automatically independent evidence

Source access

Primary-publication records linked; full-text versus abstract review shown per source

Safety evidence

Clinical safety, product equivalence and interactions not established by this collection

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

Three historical abstracts describe Vilosen, a nonprotein thymus extract. Two reports combined it with Splenin. The full methods, group sizes and numerical outcomes remain unavailable.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗

Explore the expanded peptide research collection and unresolved source trails ↗

View this preparation in the Khavinson evidence map ↗

03 / SOURCE RECORDS

Findings by study

Explore related research ↗

Observational study · 1990

The effect of vilozen on the immune status of bronchial asthma patients

The report describes immune abnormalities in 163 asthma patients and improvement with adjunctive Vilosen in atopic-associated asthma. It supplies no treated-arm denominator or numerical symptom response.

Study notes and original source
1990Uncontrolled human reportEnglish abstract

The effect of vilozen on the immune status of bronchial asthma patients

Native nonprotein animal-thymus extract; not synthetic Vilon · Journal publication

Kogosova LS, Kovalenko NN, Strafun OV, Markov AE · Vrachebnoe delo 1990

The report describes immune abnormalities in 163 asthma patients and improvement with adjunctive Vilosen in atopic-associated asthma. It supplies no treated-arm denominator or numerical symptom response.

Results and tables

Reported findings and study design

The report describes immune abnormalities in 163 asthma patients and improvement with adjunctive Vilosen in atopic-associated asthma. It supplies no treated-arm denominator or numerical symptom response.

163 bronchial-asthma patients underwent immune assessment; the abstract does not specify how many received Vilosen.

Results · Primary-publication indexed abstract
MeasureResultComparison, timing and statistics
Reported responseImmune correction and clinical improvement described in atopic-associated asthma; no response rate supplied
Assessed population163 patients; treated subset not stated

The 163 assessed patients are not a verified treatment-arm count. Background treatment and uncontrolled selection prevent attributing clinical benefit to the extract alone.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
163 bronchial-asthma patients underwent immune assessment; the abstract does not specify how many received Vilosen.
Source reviewed
Original-publication metadata and indexed abstract checked in Europe PMC. No unavailable full-text figures inferred.
Study limitations
  • The 163 assessed patients are not a verified treatment-arm count. Background treatment and uncontrolled selection prevent attributing clinical benefit to the extract alone.

Reviewed 2026-11-01.

Read the source ↗

Comparison in people · 1993

The immunomodulating effect of vilozen and splenin in the treatment of patients with acute and chronic toxic-allergic hepatitis

Vilosen plus Splenin was reported to speed clinical and immune normalization when added to usual hepatitis treatment. Of 181 patients assessed, 60 are explicitly described as receiving the combination.

Study notes and original source
1993Human comparative studyEnglish abstract

The immunomodulating effect of vilozen and splenin in the treatment of patients with acute and chronic toxic-allergic hepatitis

Thymus extract plus separate spleen-derived preparation · Journal publication

Frolov VM, Peresadin NA, Vysotskiĭ IIu, Tishchenko AN, Pinskiĭ LL · Likars'ka sprava 1993

Vilosen plus Splenin was reported to speed clinical and immune normalization when added to usual hepatitis treatment. Of 181 patients assessed, 60 are explicitly described as receiving the combination.

Results and tables

Reported findings and study design

Vilosen plus Splenin was reported to speed clinical and immune normalization when added to usual hepatitis treatment. Of 181 patients assessed, 60 are explicitly described as receiving the combination.

65 acute and 116 chronic toxic-allergic hepatitis patients examined; 20 acute and 40 chronic patients received add-on Vilosen plus Splenin.

Results · Primary-publication indexed abstract
MeasureResultComparison, timing and statistics
Combination resultFaster clinical-index and immune-homeostasis normalization reported; no numerical effect supplied
Explicitly treated subset20 acute + 40 chronic patients
Treatment course10–15 days; Vilosen plus intramuscular Splenin and usual care

No numerical between-group outcome or allocation method is supplied. Splenin and background therapy prevent isolating Vilosen. The abstract’s intranasal/sublingual dose wording is ambiguous.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
65 acute and 116 chronic toxic-allergic hepatitis patients examined; 20 acute and 40 chronic patients received add-on Vilosen plus Splenin.
Source reviewed
Original-publication metadata and indexed abstract checked in Europe PMC. No unavailable full-text figures inferred.
Study limitations
  • No numerical between-group outcome or allocation method is supplied. Splenin and background therapy prevent isolating Vilosen. The abstract’s intranasal/sublingual dose wording is ambiguous.

Reviewed 2026-11-01.

Read the source ↗

Observational study · 1996

The efficacy of immunomodulating therapy in patients with chronic cholestatic liver diseases

The combined extract regimen was associated with improved immune and microcirculatory measures and longer remission in chronic cholestatic liver disease. The abstract gives no remission duration or response percentage.

Study notes and original source
1996Uncontrolled human reportEnglish abstract

The efficacy of immunomodulating therapy in patients with chronic cholestatic liver diseases

Thymus extract combined with Splenin · Journal publication

Petrunia AM, Enenko IuA · Likars'ka sprava 1996

The combined extract regimen was associated with improved immune and microcirculatory measures and longer remission in chronic cholestatic liver disease. The abstract gives no remission duration or response percentage.

Results and tables

Reported findings and study design

The combined extract regimen was associated with improved immune and microcirculatory measures and longer remission in chronic cholestatic liver disease. The abstract gives no remission duration or response percentage.

93 patients with chronic cholestatic liver disorders; combined Splenin/Vilosen treatment.

Results · Primary-publication indexed abstract
MeasureResultComparison, timing and statistics
Clinical findingsImproved clinical measures and longer remission reported; no duration supplied
Study population93 patients

No isolated Vilosen arm or numerical clinical comparison is described.

Source for these results ↗ · Reviewed 2026-11-01

Population / setting
93 patients with chronic cholestatic liver disorders; combined Splenin/Vilosen treatment.
Source reviewed
Original-publication metadata and indexed abstract checked in Europe PMC. No unavailable full-text figures inferred.
Study limitations
  • No isolated Vilosen arm or numerical clinical comparison is described.

Reviewed 2026-11-01.

Read the source ↗

Animal research · 1994

[Radiation protective effect of low molecular weight thymus preparations].

The abstract discusses low-molecular-weight thymic preparations in radiation injury; it does not provide enough methods to establish a human controlled study.

Study notes and original source
1994Animal / experimentalEnglish abstract

[Radiation protective effect of low molecular weight thymus preparations].

Preparation-specific research; no equivalence inferred

Baraboĭ VA, Ialkut SI, Savtsova ZD, Zinchenko VA, Zhukova VM, Zaritskaia MIu. · Radiatsionnaia biologiia, radioecologiia

The abstract discusses low-molecular-weight thymic preparations in radiation injury; it does not provide enough methods to establish a human controlled study.

Population / setting
See original report; human, animal and laboratory components must be distinguished.
Source reviewed
Indexed metadata and abstract checked via Europe PMC. Original full methods not reviewed. Study type is based on the database record and abstract, where available.
Study limitations
  • The abstract leaves the preparation and study methods unclear.
  • Related publications may share experiments; source count is not independent-study count.

Reviewed 2026-10-02.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗